Drug Database
SI

silibinin sodium hemisuccinate (Legalon Sil)

✓ Approved

Rottapharm Madaus · · Small Molecule

What is silibinin sodium hemisuccinate?

silibinin sodium hemisuccinate is a small molecule developed by Rottapharm Madaus. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or oral (po).

Drug Profile

Brand NamesLegalon Sil
CompanyRottapharm Madaus
Drug ClassSmall Molecule
RouteInjectable (Others), Intravenous (IV), Oral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

silibinin sodium hemisuccinate acts on 1 molecular target:

polyprotein, hepatitis-C virus (POLY)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

silibinin sodium hemisuccinate is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Injury, poisoning and procedural complicationsPoisoning✓ Approved
Infections and infestationsHepatitis CPhase III

Related Research Articles

PubMedEuropean journal of sport science2026-07-25

Gastrointestinal Symptoms Associated With Sodium Bicarbonate Supplementation Protocols: A Systematic Review.

Winter Ian P IP, Sarac Paul P, Wilson Patrick B PB

Sodium bicarbonate positively impacts performance, but its associated gastrointestinal symptoms (GIS) may limit use. This systematic review synthesized literature that has evaluated GIS with sodium bicarbonate supplementation. Literature searches were performed from February 2024-March 2026. Eligible studies provided ≥ 5 g of sodium bicarbonate within a 24-h period or, if a multi-day protocol, at least one day involving ≥ 5 g. Included studies had a placebo group/condition or a comparison group/condition that created a contrast related to delivery method, form, or dose. In total, 101 investigations were summarized in six categories: acute single dosing (n = 35); acute spread dosing (n = 28); chronic dosing (n = 7); acute versus chronic dosing (n = 5); delivery form (n = 18); and other (n = 8). Existing literature suggests that common acute doses (0.2-0.4 g/kg) elicit mild-to-severe GIS, which likely increase in a dose-dependent manner when sodium bicarbonate is ingested in a single dose. Strategies to reduce GIS with acute dosing include spreading intake over hours, using enteric-coated capsules/tablets, and ingesting sodium bicarbonate mini-tablets within a carbohydrate hydrogel. Direct comparisons of these strategies to reduce GIS are absent in current literature; thus, ranking their effectiveness is not possible. Multi-day dosing may lessen GIS, but symptom documentation throughout supplementation periods is poorly characterized. Notably, 26 of 101 studies failed to perform inferential statistical testing to examine condition/group differences in GIS. Making definitive recommendations about sodium bicarbonate supplementation to minimize GIS remains challenging. Major needs remain for direct comparisons between protocols purported to reduce GIS and improvements in GIS data collection, reporting, and analysis.

PubMedDevelopmental medicine and child neurology2026-07-25

Seizure worsening and sodium-channel blockers in HCN1-related epilepsies: A case series.

PubMedEnvironmental research2026-07-25

Fabrication of a Tripolyphosphate-Modified Chitosan-Sodium Alginate Composite for Highly Efficient Uranium Adsorption from Water.

Zhong Xingyu X, Yang Fang F, Lu Lihong L, Zhang Wenqing W et al.

The preparation of composite materials with excellent adsorption capacity for uranium in water remains a topic of great interest. In this work, a novel composite adsorbent, tripolyphosphate-modified chitosan-sodium alginate (PCSSA), was successfully prepared by incorporating sodium alginate into tripolyphosphate-modified chitosan via chemical cross-linking. The resulting material exhibited excellent adsorption capacity for U(VI) in aqueous solutions. Within the chitosan matrix, amino, alkyl, and phosphate groups act synergistically to form amino-alkyl phosphate ligands (NH2-CH2-PO43-) with chelating functionality, providing abundant adsorption sites for efficient U(VI) removal. SEM and EDS characterization revealed a rugged, plate-like surface morphology, loaded with functional groups such as phosphate and carboxyl/hydroxyl groups. Systematic adsorption experiments indicated that the U(VI) adsorption behavior of PCSSA follows the Langmuir isotherm and the Elovich kinetic model. Under optimal conditions (pH = 3, 298.15 K, adsorbent dose = 30 mg), the maximum adsorption capacity reached 561.86 mg·g-1. In real water samples with a low U(VI) concentration (30 mg·L-1), the removal efficiency was as high as 88%, outperforming many similar bio-based adsorbents. FTIR and XPS analyses suggested that the phosphate groups interact with UO22+ through multiple mechanisms, including electrostatic attraction, ligand exchange, and complexation. The PCSSA composite is environmentally friendly and straightforward to prepare, showing promising potential for application in water pollution control.

PubMedInternational journal of biological macromolecules2026-07-25

Controlled release network hydrogel based on zein/sodium alginate-stabilized chrysanthemum essential oil Pickering emulsions for prolonged preservation of fresh-cut Gastrodia elata.

Zhang Lihui L, Liu Jieni J, Law Chung Lim CL, Sun Qing Q et al.

Browning and microbial proliferation are major factors driving quality deterioration in fresh-cut Gastrodia elata. This study developed a zein/sodium alginate-stabilized chrysanthemum essential oil (CEO) Pickering emulsion and incorporated it into gelatin-konjac glucomannan hydrogels for fresh-cut G. elata preservation. The emulsion exhibited nanoscale droplets (194.53-515.00 nm) with exceptional stability (zeta potential: -82.85 to -95.92 mV), confirming effective encapsulation of CEO. The optimized hydrogel (GK-8%) formed a dense network with uniform pore structure, demonstrating superior water retention and sustained release properties, achieving 73.30% CEO release over 390 h. Application tests revealed that GK-8% significantly reduced weight loss (≤ 0.15%) and browning index (26.72% reduction), maintained firmness and total phenolic content, while decreasing antioxidant enzyme activities, indicating reduced oxidative stress. Visual observations showed that GK-8% treatment delayed visible browning by approximately 3 days compared to the control. The hydrogel extended shelf life through synergistic effects of microbial inhibition and oxidative stress alleviation, providing an effective, eco-friendly strategy for fresh-cut product preservation.

PubMedIndian journal of clinical biochemistry : IJCB2026-07-25

Short-Chain Fatty Acids Ameliorates Lipid Profile, Oxidative Stress and Inflammation in Letrozole Induced Polycystic Ovary Syndrome Rat Model.

Acharya Ashwitha A, Shetty Prasanna Kumar PK, Sonkusare Shipra S, Padmanabha Ganeshkodi Roopashree R et al.

Polycystic ovary syndrome (PCOS) is one of the most common metabolic-reproductive disorders affecting reproductive-age women, causing an irregular menstrual cycle, hyperandrogenism, and polycystic ovarian morphology. Current therapies for PCOS focus on the management of symptoms. Short-chain fatty acids (SCFAs) play a significant role in PCOS by influencing the gut microbiota composition and metabolic pathways. The impact of short-chain fatty acids (SCFAs) on lipid profiles, inflammatory markers, and oxidative stress parameters in the PCOS model remains unclear. The present study aimed to elucidate the effect of SCFA on lipid profile, oxidative stress parameters, and inflammation in a high-fat diet-fed letrozole-induced PCOS model. 48 Female albino Wistar rats were randomised to 8 group (n = 6). The groups were treated with letrozole to induce PCOS and then treated with sodium acetate (SA), sodium propionate (SP), sodium butyrate (SB), and SCFA (3:1:1) mixture. This study observed a significant distortion in lipid profile, oxidative stress parameters and inflammatory markers. Our data showed, PCOS model showed elevated levels of triglycerides and very-low-density lipoprotein, which were significantly ameliorated when treated with SCFA (3:1:1), SA, SP, and SB. SP, SB, and SCFA (3:1:1) significantly lowered total cholesterol, while only SB and SCFA (3:1:1) significantly lowered low-density lipoprotein-cholesterol. Elevated high-density lipoprotein-cholesterol was observed in the SA, SB, and SCFA (3:1:1) treated group. The malondialdehyde level was lowered in the SCFA-treated groups, whereas the total antioxidant capacity, superoxide dismutase, and glutathione level was elevated. Our data showed a significant reduction in IL-6, IL-1β levels in the PCOS-induced group treated with SA, SP, SB, and SCFA (3:1:1). The findings of the present study suggest that short-chain fatty acids restructure dyslipidemia, oxidative stress and inflammation in a PCOS-induced model, highlighting their possible role as therapeutic dietary supplements in alleviating PCOS.

PubMedInternational journal of dental hygiene2026-07-25

Comparative Evaluation of Chlorhexidine, Citric Acid, and Sodium Chloride Solutions for Toothbrush Decontamination: A Pilot Exploratory Interventional Study.

Kaukab Azra A, Shukla Khushi K, Vishwanath Aishwarya A, Srivatsa Devalla Ananth DA et al.

To compare the effectiveness of three commonly used solutions for toothbrush decontamination, namely, 0.12% chlorhexidine gluconate (CHX), 20% citric acid (CA), and 3.5% sodium chloride (NaCl) solutions. Fifty-one study participants were given toothbrushes and instructed to brush twice daily. The participants were randomly divided into three experimental groups based on the solution used for decontamination-0.12% CHX (Group A), 20% CA (Group B), and 3.5% NaCl (Group C). After 3 months, the toothbrush heads were collected from the participants and the pretest colony-forming units (CFU) counts were determined. They were then immersed in the respective solutions for 7 h, after which the CFU counts were again determined. A Wilcoxon signed-rank test was used to compare the differences in the pretest and posttest CFU counts. A Kruskal-Wallis test was used to compare the mean percentage reduction in CFU counts for samples in the three groups, followed by Dunn-Bonferroni's post hoc test for intergroup comparisons. There was a statistically significant reduction in CFUs in all three groups tested. CA solution (20% concentration) was comparable to the gold standard CHX when it came to CFU reduction (p ≤ 0.05). Both solutions showed a 99.9% reduction in the colony-forming unit count, whereas 3.5% NaCl solution only showed a 12.2% reduction. 0.12% CHX and 20% CA solution showed the maximum percentage reduction in CFUs. CA demonstrated potential as an effective toothbrush decontaminant due to its lower cost and safer profile. Clinical trial registry, India: CTRI/2020/11/028920.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about silibinin sodium hemisuccinate